Docoh
Loading...

228 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
PRPO Precipio Inc
12 Aug 21
Quarterly report
4:07pm
, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient … and reimbursement terms and changes in customer base and payer/product mix. The billing functions for the remaining portion of our revenue
10-Q
2021 Q1
PRPO Precipio Inc
14 May 21
Quarterly report
4:01pm
, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse … and reimbursement terms and changes in customer base and payer/product mix. The billing functions for the remaining portion of our revenue
DEF 14A
PRPO Precipio Inc
29 Apr 21
Definitive proxy
4:31pm
of the plans applicable thereto (and any applicable laws and regulations); and (iii) reimbursement under the Agreement for expenses incurred prior … of termination, subject to the terms of the plans applicable thereto (and any applicable laws and regulations); and (iii) reimbursement under
424B5
PRPO Precipio Inc
2 Apr 21
Prospectus supplement for primary offering
2:00pm
improvements to our existing products and services; our ability or the amount of time it will take to achieve successful reimbursement of our existing … reimbursement levels (approximately $600 for full panel at Medicare rates) and given the costs to run the tests, laboratories running the test in house
10-K
2020 FY
PRPO Precipio Inc
29 Mar 21
Annual report
4:29pm
believe physician ordering patterns for the test are encumbered by the economics (reimbursement less costs to test) and length of time (2 to 4 weeks … substantial reductions in both time and cost to test for these genetic mutations. At the current reimbursement levels (approximately $600 for the full
10-Q
2020 Q3
PRPO Precipio Inc
13 Nov 20
Quarterly report
4:01pm
, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse … unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payer/product
10-Q
2020 Q2
PRPO Precipio Inc
13 Aug 20
Quarterly report
3:07pm
requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations … criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base
424B3
PRPO Precipio Inc
7 Jul 20
Prospectus supplement
5:27pm
reimbursement levels (approximately $600 for full panel at Medicare rates) and given the costs to run the tests, laboratories running the test in house … Developed Test). At an average reimbursement rate of approximately $600 per test, the US Market Revenue Potential is approximately $84 million per
S-1
PRPO Precipio Inc
26 Jun 20
IPO registration
5:18pm
, and the speed of which the results are delivered, may significantly impact patient care. At the current reimbursement levels (approximately $600 for full … (Research Use Only) basis, and a laboratory can set up the test In-house test as an LDT (Laboratory Developed Test). At an average reimbursement rate
10-Q
2020 Q1
PRPO Precipio Inc
14 May 20
Quarterly report
4:05pm
healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has … , historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payer/product mix. The billing
DEF 14A
PRPO Precipio Inc
29 Apr 20
Definitive proxy
4:32pm
date of termination, subject to the terms of the plans applicable thereto (and any applicable laws and regulations); and (iii) reimbursement under … laws and regulations); and (iii) reimbursement under the Agreement for expenses incurred prior to the effective date of termination, subject
424B3
PRPO Precipio Inc
13 Apr 20
Prospectus supplement
4:55pm
significantly impact patient care. At the current reimbursement levels (approximately $600 for full panel at Medicare rates) and given the costs to run … the test In-house test as an LDT (Laboratory Developed Test). At an average reimbursement rate of approximately $600 per test, the US Market Revenue
S-3/A
PRPO Precipio Inc
9 Apr 20
Shelf registration (amended)
1:53pm
the importance, and the speed of which the results are delivered, may significantly impact patient care. At the current reimbursement levels (approximately … reimbursement rate of approximately $600 per test, the US Market Revenue Potential is approximately $84 million per year, in addition to international
S-3/A
EX-4.2
PRPO Precipio Inc
9 Apr 20
Shelf registration (amended)
1:53pm
or letters of credit or bankers’ acceptances (or, without double counting, reimbursement agreements in respect thereof); (iii) representing the deferred … and reimbursement of its expenses while acting as Trustee. Within one (1) year after the successor Trustee takes office, the Holders of at least a majority
S-1/A
PRPO Precipio Inc
8 Apr 20
IPO registration (amended)
3:41pm
impact patient care. At the current reimbursement levels (approximately $600 for full panel at Medicare rates) and given the costs to run the tests … In-house test as an LDT (Laboratory Developed Test). At an average reimbursement rate of approximately $600 per test, the US Market Revenue
10-K/A
2019 FY
PRPO Precipio Inc
7 Apr 20
Annual report (amended)
2:26pm
) reimbursement under the Agreement for expenses incurred prior to the effective date of termination, subject to the terms of the agreement and the policies … (and any applicable laws and regulations); and (iii) reimbursement under the Agreement for expenses incurred prior to the effective date of termination
S-3
PRPO Precipio Inc
27 Mar 20
Shelf registration
4:51pm
, and the speed of which the results are delivered, may significantly impact patient care. At the current reimbursement levels (approximately $600 for full … (Research Use Only) basis, and a laboratory can set up the test In-house test as an LDT (Laboratory Developed Test). At an average reimbursement rate
S-1
PRPO Precipio Inc
27 Mar 20
IPO registration
4:31pm
. At the current reimbursement levels (approximately $600 for full panel at Medicare rates) and given the costs to run the tests, laboratories running … as an LDT (Laboratory Developed Test). At an average reimbursement rate of approximately $600 per test, the US Market Revenue Potential is approximately $84
8-K
EX-10.1
PRPO Precipio Inc
27 Mar 20
Entry into a Material Definitive Agreement
4:19pm
, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
10-K
2019 FY
PRPO Precipio Inc
27 Mar 20
Annual report
3:47pm
are delivered, may significantly impact patient care. At the current reimbursement levels (approximately $600 for full panel at Medicare rates … , and a laboratory can set up the test In-house test as an LDT (Laboratory Developed Test). At an average reimbursement rate of approximately $600 per test